From DCAT Value Chain Insights (VCI)
Recipharm, a contract development and manufacturing organization, has appointed Yves Buelens to the position of general manager for its wholly owned new subsidiary Kaysersberg Pharmaceuticals SAS.
Mr. Buelens has a master in pharmaceutical sciences from the University of Brussels, Belgium and a specialisation as industrial pharmacist (QP). He brings a broad experience to the Group acquired
in various roles in the pharmaceutical industry as well as in contract manufacturing organisations in Europe. He has been the plant manager for the Kaysersberg facility since 2014.
Kaysersberg Pharmaceuticals employs around 260 people. The company, including its main asset a manufacturing facility in Alsace, France, was acquired by Recipharm December 31, 2015. The facility was
previously acquired by Alcon in 1984. Alcon is the second largest division of Novartis. The facility is dedicated to blow fill sea/form fill seal technology. The facility manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription